Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome

被引：0
|
作者：
Marcel Merchan, Brayan [1 ]
Ortega, Margarita [1 ]
Jose Llamas-Poyato, Mara [2 ]
Cortes, Montserrat [3 ]
Arnan, Montserrat [4 ]
Cervero, Carlos [5 ]
Montoro, Julia [1 ]
Gimenez, Teresa [6 ]
Lopez, Mara [7 ]
Arenillas, Leonor [8 ]
Valcarcel, David [1 ]
机构：
[1] Univ Hosp Vall dHebron, Barcelona, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Fundacio Hosp Asil, Dept Hematol, Granollers, Spain
[4] Inst Catala Oncol Duran & Reynals, Barcelona, Spain
[5] Hosp Virgen La Luz, Dept Hematol, Cuenca, Spain
[6] Hosp Joan 23, Tarragona, Spain
[7] Hosp Univ La Fe, Valencia, Spain
[8] Hosp del Mar, GRENTHE, IMIM Hosp del Mar Res Inst, Barcelona, Spain
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Xiao, Lianchun
    Najla, Al Ali
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Bryan, Jeffery
    Prescott, Hillary
    Steensma, David P.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    List, Alan
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    [J]. BLOOD, 2013, 122 (21)
  • [22] Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 127 - 129
  • [23] Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study
    Villegas, Ana
    Arrizabalaga, B.
    Fernandez-lago, C.
    Mouzo, M.
    Mayans, Jr
    Gonalez-Porras, Jr
    Duarte, Rafael
    Remacha, Angel Francisco
    Luno, Elisa
    Gasquet, J. A.
    [J]. BLOOD, 2008, 112 (11) : 1184 - 1184
  • [24] Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
    Abaza, Yasmin
    Hidalgo-Lopez, Juliana E.
    Verstovsek, Srdan
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Estrov, Zeev
    Alvarado, Yesid
    Burger, Jan
    Schneider, Heather
    Soltysiak, Kelly A.
    Wei, Yue
    Kantarjian, Hagop M.
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. LEUKEMIA RESEARCH, 2018, 73 : 78 - 85
  • [25] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)
    Gasal, E.
    Pan, C.
    Tankersley, C.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S166 - S167
  • [26] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
  • [27] Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.
    Jabbour, Elias J.
    Daver, Naval G.
    Dong, Tina
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Ghanem, Hady
    Faderl, Stefan
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2012, 120 (21)
  • [28] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    [J]. BLOOD, 2014, 124 (21)
  • [29] Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Wang, Xuemei
    Abruzzo, Lynne V.
    Cornelison, A. Megan
    O'Brien, Susan
    Ravandi, Farhad
    Kadia, Tapan
    Borthakur, Gautam
    Estrov, Zeev
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2011, 118 (21) : 1624 - 1624
  • [30] Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
    Santini, Valeria
    Schemenau, Jennifer
    Levis, Alessandro
    Balleari, Enrico
    Sapena, Rosa
    Ades, Lionel
    Guerci, Agnes
    Beyne-Rauzy, Odile
    Gourin, Marie-Pierre
    Cheze, Stephane
    Stamatoullas, Aspasia
    Sanna, Alessandro
    Gioia, Daniela
    Cametti, Gianni
    Ferrero, Dario
    Raffoux, Emmanuel
    Rose, Christian
    Poloni, Antonella
    Prebet, Thomas
    Legros, Laurence
    Natarajan-Ame, Shanti
    Fenaux, Pierre
    Germing, Ulrich
    Dreyfus, Francois
    Park, Sophie
    [J]. BLOOD, 2013, 122 (13) : 2286 - 2288
12345